An administrative decide dominated Illumina’s $eight billion acquisition of cancer-testing firm Grail didn’t violate antitrust legislation, Illumina mentioned on Thursday.
A Federal Commerce Fee lawsuit threatened to unwind Illumina’s acquisition of Grail, a blood testing firm that screens for cancers at an early stage.
“As we’ve said from the outset, this transaction is procompetitive, will advance innovation, decrease healthcare prices and save lives,” Illumina basic counsel Charles Dadswell mentioned in an announcement.
Preserve studying Endpoints with a free subscription
Unlock this story immediately and be part of 149,500+ biopharma execs studying Endpoints every day — and it is free.
